Table 1.
Patient characteristics.
| Category | N | % | < 5 CTC | ≥ 5 CTC | p-Value |
|---|---|---|---|---|---|
| Age | 0.968 | ||||
| < 65 years | 31 | 26 | 10 | 19 | |
| ≥ 65 years | 89 | 74 | 27 | 58 | |
| WHO performance score | 0.045 | ||||
| 0 | 61 | 51 | 24 | 33 | |
| 1 | 59 | 49 | 13 | 44 | |
| Type of castration | 1.000 | ||||
| Surgical | 15 | 13 | 5 | 10 | |
| LHRH agonist | 105 | 88 | 32 | 67 | |
| Prior chemotherapy lines | |||||
| 1 (only docetaxel) | 119 | 99 | 37 | 76 | |
| 2 | 1 | 1 | 0 | 1 | |
| Prior antiandrogen therapy for mCRPC * | 0.326 | ||||
| Abiraterone | 23 | 19 | 10 | 12 | |
| Enzalutamide | 9 | 8 | 2 | 7 | |
| Orteronel | 12 | 10 | 3 | 9 | |
| None | 77 | 64 | 23 | 49 | |
| Baseline chemistry | Median | Range | Median (range) | Median (range) | |
| LDH U/L (n = 118) | 312 | 141–1843 | 237.5 (151–531) | 353 (141–1843) | 0.001 |
| ALP U/L (n = 119) | 128 | 39–909 | 105 (43–409) | 174 (39–909) | <0.001 |
| PSA μg/L (n = 120) | 152 | 4.5–5300 | 120 (45–2000) | 175 (7–5300) | 0.519 |
| CTC count (n = 114) | 15.5 | 0–1025 | 1 (0–4) | 51 (5–1025) |
Patients characteristics of the 120 patients included in this study. Note: CTC = circulating tumor cells, LHRH agonist = luteinizing hormone-releasing hormone agonist; mCRPC = metastatic castration-resistant prostate cancer; ALP = alkaline phosphatase; LDH = lactate dehydrogenase; PSA = prostate specific antigen. * One patient received enzalutamide and orteronel sequentially. CTC counts are from baseline CTC enumeration.